Advancing the Alzheimer’s Disease Research and Care Pipeline with Agentic Artificial Intelligence: Opportunities, Challenges, and Priorities from the International Clinical Trials on Alzheimer’s Disease (CTAD) Task Force - 17/09/26

Doi : 10.1016/j.tjpad.2026.100678

Laure Rouch ^1,^2,^⁎ , Lefkos Middleton ³, Paul Aisen ⁴, Michael Weiner ⁵, Zoe Kourtzi ⁶, Pedro Pinheiro-Chagas ⁷, Rachel Nosheny ^8,^9,¹⁰, Katherine Possin ⁷, Bruno Vellas ^1,², Niranjan Bose ¹¹, Sandrine Andrieu ^1,²

the EU/US CTAD Task Force members ^{^#}
EU/US CTAD Task Force members: Grigor Abelian (Lawrenceville, Usa); Gabrielle Ahlberg Hillert (Stockholm, Sweden); Paul Aisen (San Diego, USA); Katerina Akassoglou (San Francisco, USA); Sandrine Andrieu (Toulouse, France); Davide Angioni (Toulouse, France); Phyllis Barkman Ferrell (USA); Matthew Barton (Atlanta, USA); Randall Bateman (St Louis, USA); Margaux Bennett (Sacramento, USA); Kinal Bhatt (Brea, USA); Sarah Biber (St Louis, USA); Alessandro Biffi (Indianapolis, USA); Olga Björklund (Stockholm, Sweden); Niranjan Bose (Kirkland, USA); Sasha Bozeat (Basel, Switzerland); Joel Braunstein (St Louis, USA); Dawn Brooks (Indianapolis, USA); Holly Brothers (Cambridge, USA); Szofia Bullain (Cambridge, USA); Marc Cantillon (Livingston, USA); Siddharthan Chandran (Edinburgh, UK); Allen Chen (Cambridge, USA); Matthew Clement (Kirkland, USA); Bryan Cobb (Nutley, USA); Nicola Coley (Toulouse, France); Jeffrey Cummings (Las Vegas, USA); Charles DeCarli (Sacramento, USA); Shobha Dhadda (Nutley, USA); Michael Donohue (San Diego, USA); Billy Dunn (USA); John Dwyer (Washington DC, USA); Michael Egan (North Wales, USA); Fanny Elahi (New York, USA); Cheng Fang (Malvern, USA); Howard Fillit (New York, USA); Lisa Fosdick (Cambridge, USA); Cory Funk (Seattle, USA); Hideki Garren (South San Francisco, USA); Devin Gilliam (Yardley, USA); Danielle Graham (Cambridge, USA); Carlos Granda (Lawrenceville, USA); Steven Greenberg (Boston, USA); Michael Grundman (San Diego, USA); Joshua Hare (Miami, USA); Karra Harrington (New Haven, USA); Suzanne Hendrix (Salt Lake City, USA); Joe Herring (North Wales, USA); Steven Hersch (Nutley, USA); Jason Hinman (Los Angeles, USA); Carole Ho (South San Francisco, USA); Theresa Hudson (Lawrenceville, USA); Elaine Hughes (Lawrenceville, USA); Farhad Imam (Kirkland, USA); Mireille Jacobson (San Diego, USA); Ross Jeggo (Cambridge, USA); Gustavo Jimenez-Maggiora (San Diego, USA); Anja Kahl (Lawrenceville, USA); Aaron Kantor (Sacramento, USA); Geoffrey Kerchner (Basel, Switzerland); Ralph Kern (Cambridge, USA); Gene Kinney (San Francisco, USA); Zoe Kourtzi (Cambridge, UK); Akihiko Koyama (Nutley, USA); Luka Kulic (Basel, Switzerland); Anahita Kyani (Raritan, USA); Jaren Landen (Raritan, USA); Eric Landsness (St Louis, USA); Christopher Lane (Basel, Switzerland); Roger Lane (Carlsbad, USA); John Lawson (Hilton Head, USA); Melissa Lee (New York, USA); Ralph Lee (Irvine, USA); Cynthia Lemere (Boston, USA); Codrin Lungu (Cambridge, USA); Paresh Malhotra (London, UK); Sarah Marbach (Cambridge, USA); Donna Masterman (South San Francisco, USA); Manny McBride (Kirkland, USA); Justin Melendez (St Louis, USA); Lefkos Middleton (London, UK); Mark Mintun (Indianapolis, USA); Doris Molina-Henry (San Diego, USA); YoungJoon Moon (Seoul, Korea); Gregory Moore (Kirkland, USA); Jennifer Murphy (Cambridge, USA); Sarah Naylor (St Louis, USA); Tara Nickerson (Sacramento, USA); Laura Nisenbaum (New York, USA); Rachel Nosheny (San Francisco, USA); Sid O’Bryant (Fort Worth, USA); Gunilla Osswald (Stockholm, Sweden); Winnie Pak (La Jolla, USA); Pedro Pinheiro-Chagas (San Francisco, USA); Katherine Possin (San Francisco, USA); Jeremy Pruzin (Phoenix, USA); Mary Quiceno (San Francisco, USA); Gil Rabinovici (San Francisco, USA); Michael Rafii (Los Angeles, USA); Rema Raman (San Diego, USA); Brian Rash (Miami, USA); Larisa Reyderman (Nutley, USA); Robert Rissman (San Diego, USA); Kaleigh Roberts (St Louis, USA); Laure Rouch (Toulouse, France); Carrie Rubel (Cambridge, USA); Ivana Rubino (Cambridge, USA); Pallavi Sachdev (Nutley, USA); Ricardo Sainz Fuertes (Nutley, USA); Stephen Salloway (Providence, USA); Anna Santacruz (St Louis, USA); Rachel Schindler (New York, USA); Lon Schneider (Los Angeles, USA); David Scott (San Mateo, USA); Sharon Sha (Palo Alto, USA); Ashish Shah (Lawrenceville, USA); Shardae Showell (Cambridge, USA); Eric Siemers (Newton, USA); John Sims (Indianapolis, USA); Kaycee Sink (New Haven, USA); Daniel Skovronsky (Indianapolis, USA); Heather Snyder (Chicago, USA); Ravi Solanki (Yardley, USA); Reisa Sperling (Boston, USA); Kim Staats (Boca Raton, USA); Lennert Steukers (Raritan, USA); Chad Swanson (San Francisco, USA); Ben Tiede (Wayne, USA); Jeremy Ting (Cambridge, USA); Rosanna Tortelli (Basel, Switzerland); Jacques Touchon (Montpellier, France); Dung Trinh (Irvine, USA); Bruno Vellas (Toulouse, France); Michael Weiner (San Francisco, USA); Anne White (Indianapolis, USA); Robin Wolz (London, UK); Wagner Zago (Brisbane, USA); Edward Zamrini (Irvine, USA); Jin Zhou (Nutley, USA).

¹ CERPOP, UMR 1295, Toulouse, France

² IHU HealthAge Geroscience and Prevention, Toulouse, France

³ Faculty of Medicine, School of Public Health, Imperial College London, London, UK

⁴ Alzheimer’s Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA

⁵ San Francisco VA Medical Center, San Francisco, CA, USA

⁶ Department of Psychology, University of Cambridge, Cambridge, UK

⁷ Edward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA

⁸ Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA

⁹ Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA

¹⁰ Northern California Institute for Research and Education, San Francisco, CA, USA

¹¹ Gates Ventures, Kirkland, WA, USA

^⁎ Corresponding author. Pr. Laure ROUCH, PharmD, PhD, HDR, Professor, PU-PH, CERPOP UMR 1295 Aging Team, IHU HealthAge Geroscience and Prevention, Toulouse Health University, School of Pharmacy, Toulouse University Hospital, +33 5 61 14 59 63 PU-PH CERPOP UMR 1295 Aging Team IHU HealthAge Geroscience and Prevention Toulouse Health University School of Pharmacy Toulouse University Hospital

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Sous presse. Manuscrit accepté. Disponible en ligne depuis le Thursday 17 September 2026

Abstract

Artificial Intelligence (AI) holds unprecedented potential to transform the entire Alzheimer’s Disease and related dementias (ADRD) research and care continuum. During the 2025 Clinical Trials on Alzheimer’s Disease (CTAD) conference, the EU/US CTAD Task Force reviewed recent advances in the field, highlighting the emerging role of agentic AI, and discussed priorities to guide future AI-driven innovation in ADRD. Agentic AI co-scientists are emerging as transformative tools to accelerate scientific discovery by autonomously integrating multimodal data, generating and evaluating new hypotheses, and connecting previously siloed knowledge into actionable insights. Operationalized through end-to-end translational pipelines, such platforms can also link mechanistic insights to therapeutic design by automating molecular docking and drug repurposing. Complementary initiatives are creating digital wet labs for in silico experimentation. At the same time, agentic AI is increasingly being used to address pre-discovery bottlenecks by automating data harmonization and inferring missing information through digital twins and synthetic data. AI is also reshaping next-generation ADRD clinical trials, through automated assessment of clinical outcomes, precision participant stratification, individualized disease trajectory modeling and prediction of treatment response. These approaches could substantially improve trial efficiency through responder enrichment. Importantly, AI applications are expanding beyond discovery and clinical trials to support diagnosis, care navigation, and personalized disease management. To translate the momentum surrounding AI innovation into meaningful and sustainable impact across the ADRD continuum, the Task Force identified priorities including the development of AI-ready ecosystems, closer collaboration between clinicians, researchers and computer scientists, AI-enabled optimization of clinical trials and robust ethical and governance frameworks for responsible AI adoption.

Le texte complet de cet article est disponible en PDF.

Key words : Alzheimer’s Disease, Agentic Artificial Intelligence, Digital Twins, Clinical Trials, Precision Medicine